Conventional biomarkers in oncology have been developed to guide diagnosis, prognosis, and therapy selection. Today, the number of AI-derived biomarkers is still modest and largely confined to pathology and radiology, where they assist in diagnostic pathology and image analyses. Yet, a major expansion in AI-derived biomarkers is to be expected1,2.
From Algorithms to Meaningful Biomarkers: Anchoring AI in Clinical Oncology
Annals of Oncology | | E.G.E. de Vries, E. Garralda, S. Litière
Topics: targeted-therapy, research